Altamira Therapeutics Ltd. Postemployment Benefit Expense Defined Benefit Plans
Altamira Therapeutics Ltd. (CYTOF) reported Postemployment Benefit Expense Defined Benefit Plans of $122.23 thousand for the 6-month period ending 2025-06-30, per its 6-K filed 2025-08-29.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans · last filed 2025-08-29
CHF
| Period end | Postemployment Benefit Expense Defined Benefit Plans 6 month | Postemployment Benefit Expense Defined Benefit Plans 12 month |
|---|---|---|
| 2023-12-31 | 170.63K CHF 20-F/A · filed 2024-04-22 | |
| 2023-06-30 | 86.99K CHF 6-K · filed 2023-09-12 | |
| 2022-12-31 | 263.28K CHF 20-F/A · filed 2024-04-22 | |
| 2022-06-30 | 132.78K CHF 6-K · filed 2023-09-12 | |
| 2021-12-31 | 166.99K CHF 20-F/A · filed 2024-04-22 | |
| 2021-06-30 | 66.00K CHF 6-K/A · filed 2023-08-21 | |
| 2020-12-31 | 156.84K CHF 20-F · filed 2023-05-16 | |
| 2020-06-30 | 78.25K CHF 6-K · filed 2021-09-08 | |
| 2019-12-31 | 147.77K CHF 20-F · filed 2022-04-12 | |
| 2019-06-30 | 73.79K CHF 6-K/A · filed 2020-09-17 | |
| 2018-12-31 | 110.71K CHF 20-F · filed 2021-03-31 | |
| 2018-06-30 | 202.76K CHF 6-K · filed 2019-08-15 | |
| 2017-12-31 | 378.59K CHF 20-F · filed 2020-04-16 | |
| 2016-12-31 | 342.81K CHF 20-F · filed 2019-03-14 | |
| 2015-12-31 | 282.52K CHF 20-F · filed 2018-03-22 |
USD
| Period end | Postemployment Benefit Expense Defined Benefit Plans 6 month | Postemployment Benefit Expense Defined Benefit Plans 12 month |
|---|---|---|
| 2025-06-30 | $122.23K 6-K · filed 2025-08-29 | |
| 2024-12-31 | $210.64K 20-F · filed 2025-04-30 | |
| 2024-06-30 | $102.79K 6-K · filed 2025-08-29 | |
| 2023-12-31 | $191.94K 20-F · filed 2025-04-30 | |
| 2023-06-30 | $95.39K 6-K · filed 2024-09-24 | |
| 2022-12-31 | $278.80K 20-F · filed 2025-04-30 |